NanoString Technologies, Inc. (NSTG)
(Delayed Data from NSDQ)
$27.96 USD
+0.86 (3.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $27.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.96 USD
+0.86 (3.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $27.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Quipt Home Medical Corp. (QIPT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 66.67% and 3.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 7.22% and 4.13%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
NanoString (NSTG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for NanoString (NSTG) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NanoString Technologies (NSTG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NanoString (NSTG) Grows in Translational Research With CRO Deals
by Zacks Equity Research
According to NanoString (NSTG), SMI's unique ability to interrogate both RNA and proteins at ultra-high plex with subcellular resolution has made it a one-of-a-kind tool.
NanoString (NSTG) Advances in Xenotransplantation With New Study
by Zacks Equity Research
NanoString's (NSTG) nCounter Analysis System facilitates bulk tissue transcriptome profiling, revealing the intricacies of the immune response through the nCounter Human Organ Transplant Panel.
Compared to Estimates, NanoString (NSTG) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for NanoString (NSTG) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
NanoString Technologies (NSTG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -22.22% and 8.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
NanoString Technologies (NSTG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -55.74% and 3.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
NanoString Technologies (NSTG) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -71.74% and 16.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Stryker (SYK) Misses Q3 Earnings Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of -5.36% and 0.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think NanoString (NSTG) Could Surge 116%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 116.4% upside potential for NanoString (NSTG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NanoString Technologies (NSTG) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -37.10% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: NanoString Technologies (NSTG) Q2 Earnings Expected to Decline
by Zacks Equity Research
NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts See a 172% Upside in NanoString (NSTG): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 171.7% upside potential for NanoString (NSTG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NanoString (NSTG) Surges 5.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
NanoString (NSTG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) might have struggled to maintain the recovery trend in the first half of Q1 with severe-than-expected staffing shortages and supply issues leading to procedural deferrals.
Bio-Rad (BIO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Robust uptake of dPCR products and a rebound in routine testing are likely to have contributed to Bio-Rad's (BIO) first-quarter top line.
Intuitive Surgical (ISRG) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Intuitive Surgical's (ISRG) first-quarter results reflect strong segmental performance.
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Based on a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.
Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Diagnostics and GYN Surgical businesses is likely to have contributed to Hologic's (HOLX) fiscal second-quarter revenues.
What's in Store for Boston Scientific (BSX) in Q1 Earnings?
by Zacks Equity Research
Given an innovative pipeline, expansion into faster growth markets, globalization efforts and enhanced digital capabilities, Boston Scientific (BSX) is well-positioned to register strong first quarter of 2022 results.
Abbott's (ABT) Q1 Earnings and Revenues Exceed Estimates
by Zacks Equity Research
Within Adult Nutrition, Abbott (ABT) gains from the strong performance of Ensure and Glucerna brands in Q1.
Edwards Lifesciences (EW) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) first-quarter performance.